Results 151 to 160 of about 123,893 (301)

Spatiotemporally Controlled Tumor Photodynamic/Immunotherapy Therapy Based on Upconversion Hybrid Nanosystem

Advanced Science, EarlyView.
PURH is constructed by a five‐layer upconversion nanoparticle (UCNP) surface coated with mesoporous silica, which encapsulates rose bengal (RB) within the mesoporous channels. Additionally, CpG oligonucleotides (CpG ODN) is linked to the surface, followed by the surface functionalization of hyaluronic acid (HA). This spatiotemporally controllable smart
Fang Wang, Wenfei Xu, Yuechen Liu, Shuxuan Zhu, Wenjing Liu, Shuhui Bo, Hong Sun, Bei Liu, Zhaogang Sun, Hongqian Chu   +9 more
wiley   +1 more source

Impact of a community-led intervention on the uptake of childhood vaccines in Liverpool: a protocol for a synthetic control evaluation. [PDF]

BMJ Open
Amin MS, Zhang X, Green MA, Holford D, Hemingway C, Ismail A, Moran J, Doyle V, Taylor C, Taegtmeyer M, Hungerford D.   +10 more
europepmc   +1 more source

Advanced Human Immune Cell‐Organoid Co‐Cultures for Functional Testing of Cancer Nanovaccines

Advanced Science, EarlyView.
Pancreatic ductal adenocarcinoma remains difficult to treat. We establish an organoid–immune co‐culture using patient‐derived organoids and matched T‐cells to assess cancer vaccines. A mesothelin‐targeted nanovaccine activates antigen‐specific T‐cells, increases IFN‐γ, and targets MSLN+ organoids.
Nathalia Ferreira, David Agorku, Andre Rosa, Julia Roosz, Lena Christ, Nicole Anderle, Ajinkya Kulkarni, Abir Hussein, Sana S. Sayedipour, Omar F. Luna, Tobias Legler, Philipp Ströbel, Fernando Albericio, Luis Cruz, Phillipp Beckhove, Peter Loskill, Frauke Alves, M. Andrea Markus, Fernanda Ramos‐Gomes   +18 more
wiley   +1 more source

Liposome-Based Potential Vaccines Platforms that Are Noncytotoxic. [PDF]

ChemistryOpen
Mebarek S, Jacob K, Pierro CI, Romanini D, Fiore M.   +4 more
europepmc   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Elicitation of Protective Immune Responses Against Influenza Virus Following Intranasal Delivery of Fluzone or Flublok Vaccines. [PDF]

Vaccines (Basel)
Uno N, Thomas MH, Caetano C, Ross TM.
europepmc   +1 more source

Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma [PDF]

, 2019
Artyomov, Maxim N., Bender, Diane, Campian, Jian L., Chicoine, Michael R., Dacey, Ralph G., Dunn, Gavin P., Fritsch, Edward F., Gillanders, William E., Huang, Jiayi, Johanns, Tanner M., Kobayashi, Dale K., Liu, Connor J., Mardis, Elaine R., Miller, Christopher A., Perrin, Richard J., Schreiber, Robert D.   +15 more
core   +1 more source

Soft‐Drug‐Inspired MnSTF Nano‐Adjuvant for Safe and Synergistic cGAS–STING Activation in Tumor Immunotherapy

Advanced Science, EarlyView.
This study introduces MnSTF, a soft‐drug‐inspired nanoadjuvant that overcomes the systemic toxicity of STING agonists. Through Mn2+ coordination with an ENPP1 inhibitor, it enables safe cGAS‐STING activation, remodels the tumor immune microenvironment, and synergizes with radiotherapy or vaccines to elicit robust antitumor immunity.
Guangfei Sun, Jiancheng Pan, Rui Li, Ruoxi Li, Ziyan Liu, Jinhui Wu, Tingsheng Lin, Yiqiao Hu, Ahu Yuan   +8 more
wiley   +1 more source

From pandemics to preparedness: harnessing AI, CRISPR, and synthetic biology to counter biosecurity threats. [PDF]

Front Public Health
Okon MB, Ugwu OP, Ugwu CN, Ogenyi FC, Swase DT, Anyanwu CN, Eze VHU, Ugwu JN, Akinola SA, Mujinya R, Anyanwu EG.   +10 more
europepmc   +1 more source

Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity

Advanced Science, EarlyView.
Attaching antibodies against endothelial cell surface proteins redirects the delivery and expression of DNA‐lipid nanoparticles to organs of interest. Our targeted nanoparticles enable organ‐selective DNA expression in the endothelium of the lungs, brain, or spleen, providing a therapeutic platform for dozens of endothelial‐centric diseases.
Nicolas Marzolini, Taylor V. Brysgel, Ryan J. Rahman, Eno‐Obong Essien, Saw Y. Nwe, Jichuan Wu, Aparajeeta Majumder, Manthan N. Patel, Sachchidanand Tiwari, Carolann L. Espy, Fengyi Dong, Sabrina A. Santos‐De León, Anit Shah, Vladimir V. Shuvaev, Elizabeth D. Hood, Liam S. Chase, Drew Weissman, Jeremy B. Katzen, David B. Frank, Mariko L. Bennett, Oscar A. Marcos‐Contreras, Jacob W. Myerson, Vladimir R. Muzykantov, Sahily Reyes‐Esteves, Jacob S. Brenner   +24 more
wiley   +1 more source